Previous studies reported associations of CSF biomarkers of AD (amyloid β (Aβ) and phosphorylated tau (pTau) levels) with brain atrophy, clinical symptoms, and cognitive decline in DLB [8, 9]. Here, MAPT is linked to Alzheimer disease.